Software Industry: Nexway™ Reinforces the Customer Experience Capabilities of its Monetize Personalized Growth Platform
Nexway, a leading software and service company for e-commerce and payments, is very excited to launch the latest features on its personalized growth platform Nexway Monetize, moving forward in its mission to expand the online footprint and sales potential of software vendors, games publishers and service providers across 140 countries around the world.
In today’s uncertain business environment, the e-commerce and payment leader is looking to leverage its best technologies to offer a seamless purchase experience, helping its clients to remain flexible in their strategic approach to e-commerce.
Nexway‘s teams are driving versatility, flexibility, and frictionless features to conquer new markets and expand into vertical sectors linked to customer monetization, subscriptions, and B2B sales management. Nexway also intends to continue growing thanks to its agility, expertise, and high level of the customer purchase experience.
"Customer experience is a constantly moving target, changing to meet customer needs, expectations, and evolution. Every customer has different needs and flexibility skills are crucial to adjust to situations and being able to effectively address such challenges. Being flexible with your customers is a top priority in the COVID-19 world." comments Frédéric Ribau, Chief Technical Officer and Chief Product Officer at Nexway.
To meet these expectations and context, the Company has tuned its Nexway Monetize platform with new e-commerce features and payment capabilities.
NEXWAY MONETIZE NEW FEATURES RELEASED
1/ Nexway launches multiple pre-order options available right away on the Monetize platform. This feature is mostly aimed, but not limited, at gaming publishers, allowing to convert consumers before a product/game release, to create buzz, to offer exclusivity or bonuses to its community, or simply to test its product/game. Read more.
2/ Nexway announces the evolution of its subscription capabilities and launches its subscription trial extension. This feature is intended for digital product and service providers to offer consumers a subscription with a trial period, to be renewed and extended automatically into a standard paying subscription. The trial period will be a new period integrated into the subscription model, allowing the provider to define the duration of the trial period and switch it on or off depending on his will. Read more.
3/ Nexway expands its global payment services, announcing a massive regional expansion of its payment capabilities and services. Efficiently selling in different countries requires expertise and specific capabilities. Nexway Monetize simplifies commerce with powerful payment technology and helps its customers to process payments in local currencies with the most adapted payment methods worldwide.
- Monetize supports India and the Nordics countries with local currencies and regional preferred payment methods
- In addition to Brazil, Nexway reinforces its LATAM footprint
- A range of new currencies has been implemented on Nexway’s payment platform
- Payments in installments
are now available in Brazil
- Nexway enables its clients to provide local offline payment methods
4/ To help publishers to develop their reseller network and bring differentiation to its existing reseller portal offer, Nexway has developed automatic commissions on license renewals feature for resellers. The goal of this feature is to increase the loyalty of the resellers. Read more.
“Whether B2B or B2C, today’s customers have an ever-higher expectation of service. Our challenge is to optimize the experience of our customers and support them in creating a strong differentiation and competitive advantage within the digital economy. Throughout 2021, we plan to add new solutions and features to support commerce by allowing companies to expand across borders and verticals,” adds Frédéric Ribau.
Product Documentation: Nexway Monetize
Ready to enhance customer experience and boost your global sales potential! Discover Nexway Monetize: personalized e-commerce growth platform. GET STARTED NOW
ABOUT NEXWAY
Nexway SASU is a leading e-commerce and payment player. Combining technology and managed services, Nexway helps online businesses scale, grow, and thrive. Nexway’s expertise in subscriptions, local payments, fraud prevention, and reseller management enables customers to transform their purchasing experience and accelerate sales. Founded in 2002 and headquartered in Paris–La Défense, France, Nexway has subsidiaries in the USA, Brazil, Italy, Spain, Poland, and Japan. Companies that rely on Nexway include FNAC-Darty™, Amazon™, Kaspersky™, Adobe™, Avast™, TakeTwo™, and hundreds more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005053/en/
Contact information
Media
Cécile Abescat
cabescat@nexway.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release
Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 08:00:00 EET | Press release
Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It proves a supplier has undergone an exhaustive audit of its governance, security controls, and operational processes. For Dutch financial institutions, this qualificatio
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 04:00:00 EET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 03:00:00 EET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom